Authors
Atul Deodhar, Denis Poddubnyy, Cesar Pacheco‐Tena, Carlo Salvarani, Eric Lespessailles, Proton Rahman, Pentti Järvinen, Juan Sanchez‐Burson, Karl Gaffney, Eun Bong Lee, Eswar Krishnan, Silvia Santisteban, Xiaoqi Li, Fangyi Zhao, Hilde Carlier, John D Reveille, COAST‐W Study Group, Christopher Antolini, Valderilio Azevedo, Magnus Barkham, Aaron Alejandro Barrera Rodriguez, Alberto Berman, Tomasz Blicharski, Jan Brzezicki, Gerd Burmester, Judith Carrio, Eduardo Collantes, Bernard Combe, Fidencio Cons‐Molina, Gregorio Cortes‐Maisonet, Anna Dudek, Sergio Duran Barragan, Ori Elkayam, Kathleen Flint, Mauro Galeazzi, Norman Gaylis, David Goddard, Carlos Gonzalez Fernandez, Philippe Goupille, Jordi Gratacos Masmitja, Maria Greenwald, Elisa Gremese, Seung Jae Hong, Mary Howell, Pawel Hrycaj, Akgun Ince, Ji Hyeon Ju, Jeffrey Kaine, Seong Wook Kang, Mauro Keiserman, Tae‐Hwan Kim, Alan Kivitz, Steven Klein, Joel Kremer, Sang Heon Lee, Chang Keun Lee, Sang‐Hoon Lee, Roger Lidman, James Loveless, Eleonora Lucero, Jose Maldonado Cocco, Flora Marcolino, Xavier Mariette, Daksha Mehta, Frederic Morin, Yolanda Moscovici, Eric Mueller, Eduardo Mysler, Francisco Navarro Blasco, Minh Nguyen, Carlos Pantojas, Min‐Chan Park, Amarilis Perez‐De Jesus, Eric Peters, Rafal Plebanski, Roel Querubin, Cesar Ramos Remus, Tatiana Reitblat, Tania Rivera, Juan Cruz Rizo Rodriguez, Michael Sayers, Antonio Scotton, Craig Scoville, David Shaw, Kichul Shin, Atul Singhal, Cassandra Skinner, Oscar Soto‐Raices, Martin Soubrier, Malgorzata Szymanska, Christine Thai, Marleen van de Sande, Alvin Wells, Rafal Wojciechowski, Ricardo Xavier, Antonio Ximenes, Devy Zisman
Publication date
2019/4
Journal
Arthritis & rheumatology
Volume
71
Issue
4
Pages
599-611
Description
Objective
To investigate the efficacy and safety of ixekizumab in patients with active radiographic axial spondyloarthritis (SpA) and prior inadequate response to or intolerance of 1 or 2 tumor necrosis factor inhibitors (TNFi).
Methods
In this phase III randomized, double‐blind, placebo‐controlled trial, adult patients with an inadequate response to or intolerance of 1 or 2 TNFi and an established diagnosis of axial SpA (according to the Assessment of SpondyloArthritis international Society [ASAS] criteria for radiographic axial SpA, with radiographic sacroiliitis defined according to the modified New York criteria and ≥1 feature of SpA) were recruited and randomized 1:1:1 to receive placebo or 80‐mg subcutaneous ixekizumab every 2 weeks (IXEQ2W) or 4 weeks (IXEQ4W), with an 80‐mg or 160‐mg starting dose. The primary end point was 40% improvement in disease activity according to the ASAS criteria (ASAS40 …
Scholar articles
A Deodhar, D Poddubnyy, C Pacheco‐Tena… - Arthritis & rheumatology, 2019